Fluxion, Stanford Co-Developing Tests for CTCs | GenomeWeb

NEW YORK (GenomeWeb News) – Fluxion Biosciences said today it is collaborating with the Stanford University School of Medicine to develop tests to help tailor treatments for cancer patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.